From: Maintenance therapy in NSCLC: why? To whom? Which agent?
First Author (N of randomized pts to maintenance) | Maintenance Schema | Primary End Point | Median PFS (mo) | P value | Median OS (months) | P value | References |
---|---|---|---|---|---|---|---|
Fidias P. (309) | Immediate vs delayed docetaxel | OS | 5.7 vs 2.7 | 0.0001 | 12.3 vs 9.7 | 0.08 | [26] |
Ciuleanu T. (663) | Pemetrexed vs placebo | PFS | 4.3 vs 2.6 | 0.0001 | 13.4 vs 10.6 | 0.012 | [27] |
Cappuzzo F. (889) | Erlotinib vs placebo | PFS | 12.3 vs 11.1 | 0.0001 | 12 vs 11 | 0.063 | [31] |
Perol M. (464) | Gemcitabine vs erlotinib vs placebo | PFS | 3.7 vs 2.8 vs 2.1 | nr | HR 0.86 vs 0.81 | na | [21] |
Kabbinavar F.* (768) | Bevacizumab ± Erlotinib | PFS | 4.8 vs 3.7 | 0.006 | Na | na | [32] |
Gaafar RM (173) | Gefitinib vs placebo | OS | 4.1 vs 2.9 | 0.0015 | Na | na | [33] |